Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.

Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

How do early-life exposures shape the infant skin microbiome and atopic dermatitis risk? New cohort data reveal key ...

Please provide your email address to receive an email when new articles are posted on . Samples of skin microbiota in infants showed lower levels of natural moisturizing in patients who later ...

Most patients with atopic dermatitis expressed an interest in understanding how environmental-climate factors affect their AD.

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...

The global atopic dermatitis market size was valued at USD 6.62 billion in 2025 and is predicted to hit around USD 12.97 billion by 2034, rising at a 7.75% CAGR, a study published by Towards ...